Entrada Therapeutics, Inc. (TRDA)
USD 17.1
(-7.32%)
USD 17.1
(-7.32%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 139.8 Million | -93.78 Million | -50.86 Million | -25.57 Million | -10.8 Million |
| Net Income | -6.68 Million | -94.61 Million | -51.15 Million | -26.52 Million | -5.1 Million |
| Depreciation & Amortization | 2.84 Million | 1.89 Million | 1.11 Million | 326 Thousand | 104 Thousand |
| Deferred income taxes | 2.8 Million | - | - | - | - |
| Stock-based compensation | 13.11 Million | 9.89 Million | 2.52 Million | 325 Thousand | 294 Thousand |
| Change in working capital | 136.31 Million | -11.11 Million | -3.42 Million | 282 Thousand | 174 Thousand |
| Other non-cash items | -8.58 Million | 151 Thousand | 74 Thousand | 20 Thousand | -6.27 Million |
| Investing Cash Flow | -138.39 Million | -148.65 Million | -4.58 Million | -2.31 Million | -630 Thousand |
| Investments in PPE | -5.61 Million | -2.88 Million | -4.58 Million | -2.32 Million | -630 Thousand |
| Acquisitions | - | 145.76 Million | - | 7000.00 | - |
| Investment purchases | -407.2 Million | -221.97 Million | - | - | - |
| Sales/Maturities of investments | 274.42 Million | 76.21 Million | - | - | - |
| Other Investing Activities | -132.78 Million | -145.76 Million | - | - | - |
| Financing Cash Flow | 21.03 Million | 479 Thousand | 307.46 Million | 50.08 Million | 38 Thousand |
| Debt repayment | - | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | 443 Thousand | 284 Thousand | - | - | - |
| Common Stock Issuance | 21.03 Million | 479 Thousand | 190.69 Million | 50.08 Million | 38 Thousand |
| Other Financing Activities | 21.03 Million | 479 Thousand | 116.77 Million | 50.08 Million | 38 Thousand |
| Accounts receivables | -5.87 Million | - | - | - | - |
| Accounts payables | -2.8 Million | 5.28 Million | -715 Thousand | 631 Thousand | 367 Thousand |
| Inventory | - | - | - | - | - |
| Other working capital | 144.99 Million | -16.39 Million | -2.7 Million | -349 Thousand | -193 Thousand |
| Cash at beginning of period | 45.15 Million | 291.06 Million | 39.04 Million | 16.84 Million | 28.23 Million |
| Cash at end of period | 67.6 Million | 49.1 Million | 291.06 Million | 39.04 Million | 16.84 Million |
| Capital Expenditure | -5.61 Million | -2.88 Million | -4.58 Million | -2.32 Million | -630 Thousand |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 22.44 Million | -241.95 Million | 252.01 Million | 22.2 Million | -11.39 Million |
| Free Cash Flow | 134.18 Million | -96.67 Million | -55.44 Million | -27.89 Million | -11.43 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -14.03 Million | 55.03 Million | 23.49 Million | -9.54 Million | -6.68 Million | 35.46 Million |
| Depreciation & Amortization | 937 Thousand | 910 Thousand | 934 Thousand | 736 Thousand | 2.84 Million | 834 Thousand |
| Deferred income taxes | - | - | - | -3.76 Million | 2.8 Million | - |
| Stock-based compensation | 4.86 Million | 4.62 Million | 3.73 Million | 3.84 Million | 13.11 Million | 3.39 Million |
| Change in working capital | 70.11 Million | -18.46 Million | -51.64 Million | 2.95 Million | 136.31 Million | -62.33 Million |
| Other non-cash items | -86.14 Million | -2.26 Million | -2.03 Million | 1.76 Million | -8.58 Million | -1.85 Million |
| Investing Cash Flow | -82.92 Million | -24.38 Million | 26.14 Million | 19.04 Million | -138.39 Million | -3.73 Million |
| Investments in PPE | -639 Thousand | -1.04 Million | -838 Thousand | -976 Thousand | -5.61 Million | -1.44 Million |
| Acquisitions | - | - | - | -152.8 Million | - | 2.28 Million |
| Investment purchases | -165.59 Million | -110.69 Million | -96.93 Million | -88.52 Million | -407.2 Million | -76.78 Million |
| Sales/Maturities of investments | 83.3 Million | 87.35 Million | 123.92 Million | 108.54 Million | 274.42 Million | 74.5 Million |
| Other Investing Activities | - | -23.33 Million | 26.98 Million | 20.01 Million | -132.78 Million | -2.28 Million |
| Financing Cash Flow | -11 Thousand | 101.36 Million | 206 Thousand | 690 Thousand | 21.03 Million | 368 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 263 Thousand | - | - | 443 Thousand | 443 Thousand | - |
| Common Stock Issuance | -1.96 Million | 101.36 Million | 206 Thousand | 690 Thousand | 21.03 Million | 368 Thousand |
| Other Financing Activities | 1.69 Million | 101.36 Million | 206 Thousand | 690 Thousand | 21.03 Million | 368 Thousand |
| Accounts receivables | 1.79 Million | 69.84 Million | -71.63 Million | -853 Thousand | -5.87 Million | -1.28 Million |
| Accounts payables | -314 Thousand | -886 Thousand | -655 Thousand | 2.4 Million | -2.8 Million | -1.36 Million |
| Inventory | - | - | - | 4.02 Million | - | 1.28 Million |
| Other working capital | 66.77 Million | -87.42 Million | 20.64 Million | -2.62 Million | 144.99 Million | -60.96 Million |
| Cash at beginning of period | 189.2 Million | 72.38 Million | 71.55 Million | 51.88 Million | 45.15 Million | 83.69 Million |
| Cash at end of period | 81.99 Million | 189.2 Million | 72.38 Million | 67.6 Million | 67.6 Million | 55.83 Million |
| Capital Expenditure | -639 Thousand | -1.04 Million | -838 Thousand | -976 Thousand | -5.61 Million | -1.44 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -107.2 Million | 116.81 Million | 834 Thousand | 15.72 Million | 22.44 Million | -27.86 Million |
| Free Cash Flow | -24.9 Million | 38.78 Million | -26.35 Million | -4.98 Million | 134.18 Million | -25.94 Million |
0LPE
4308
VIAAY
EME
BOLT
XELA